Medline vs Stryker
MDLN and SYK side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDLN and SYK compare
Stryker is the larger company, worth 2.7 times as much as Medline ($112B against $42.2B).
Medline grew revenue faster over the last twelve months (11.5% versus 7.9% for Stryker).
Stryker keeps more of each dollar of sales as profit, with a net margin of 13.8% compared with 4.1% at Medline.
Stryker pays a dividend yielding 1.2%; Medline does not pay one.
Stryker scores higher on the StockData Score (19 against 5 for Medline), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDLN | SYK |
|---|---|---|
| Size and price | ||
| Market cap | $42.2B | $112B |
| Share price | $32.12 | $291.86 |
| Change, 1 year | – | −21.0% |
| Change, 5 years | – | 5.7% |
| Beta (5Y) | – | 0.85 |
| Employees | 45K | 56K |
| StockData Score | ||
| Total score | 5 | 19 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 2 | 5 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 31.1× |
| P/S | 1.5× (better) | 4.3× |
| P/B | 3.6× | – |
| EV/EBITDA | 18.5× | 17.5× (better) |
| P/FCF | 32.6× | 24.5× (better) |
| PEG | – | 2.87 |
| FCF yield | 3.1% | 4.1% (better) |
| Fair value | $26.54 | $381.63 |
| Margin of safety | −21.0% | 23.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.5% (better) | 7.9% |
| Revenue growth, 5Y average | – | 11.8% |
| Net income growth (TTM) | – | 23.1% |
| EPS growth (TTM) | – | 23.4% |
| EPS growth, 5Y average | – | 14.9% |
| Profitability | ||
| Gross margin | 26.4% | 65.3% (better) |
| Operating margin | 7.8% | 20.7% (better) |
| Net margin | 4.1% | 13.8% (better) |
| FCF margin | 4.6% | 17.4% (better) |
| Return on equity | 10.0% | – |
| Return on invested capital | 9.6% | – |
| Financial health | ||
| Debt / equity | 1.09 | – |
| Net debt / EBITDA | 3.07 | 1.65 (better) |
| Interest coverage | 2.3× | 9.3× (better) |
| Current ratio | 4.33 (better) | 2.18 |
| Altman Z-score | 2.44 | 4.58 (better) |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.2% |
| Payout ratio | – | 36.8% |
| Buyback yield | 0.08% | – |
| Shareholder yield | 0.08% | 1.2% (better) |
| Ownership | ||
| Held by institutions | 57.1% | 80.2% |
| Held by insiders | 85.0% | 4.1% |
| Insider net buying, 12 months | −$13.4B | −$586M (better) |
| Superinvestors holding | 4 (better) | 1 |
| Short interest, % of float | 26.7% | 1.6% |
Go deeper
- MDLN stock overview
- MDLN income statement
- MDLN valuation and score
- SYK stock overview
- SYK income statement
- SYK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.